Newsroom

News Releases

Groundbreaking Research from UPMC Highlights Opioids’ Suppressive Impact on Immune Checkpoint Inhibitors and the Potential of Axelopran, an Opioid Antagonist to Reverse It

San Francisco, CA – December 04, 2024 – Glycyx, a clinical-stage biopharmaceutical company advancing axelopran, a novel solution to improve outcomes for cancer patients undergoing immunotherapy, today spotlighted a significant new publication in the Journal for ImmunoTherapy o...

View full release